Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: November 30, 2012

Today's headlines include news about the continuing partisan back and forth regarding "fiscal cliff" negotiations as well as reports on the health law's implementation.

30 Nov 2012

Myanmar can build more stable future by investing in vaccines, immunization

"For the first time, with support from the GAVI Alliance, a pentavalent vaccine was introduced in Myanmar this week that will defend children against five potentially fatal diseases," Dagfinn Hoybraten, vice president of the Norwegian Parliament and chair of the GAVI Alliance Board, writes in the Huffington Post's "Impact" blog, adding, "Over the next six months, more than half a million children in the country will be protected from diphtheria, pertussis, tetanus, hepatitis B (hepB), and Haemophilus influenzae type b.

29 Nov 2012

Nearly 63,000 people visit online catch-up immunization scheduling tool

Children obtain protection against certain diseases by receiving vaccinations, but they commonly miss recommended times to receive these immunizations. Once a child falls behind, health care professionals typically have to construct a unique, personalized catch-up schedule for each child - often while the child waits in the treatment room.

29 Nov 2012

Diptheria-tetanus-pertussis vaccine: an interview with Dr. Rudi Eggers, World Health Organisation

The Diptheria-tetanus-pertussis vaccine is sometimes also called the “triple vaccine” and has been around for about 50 years, and it protects against diphtheria, tetanus, and pertussis. These are serious diseases caused by bacteria.

28 Nov 2012

Microneedle-based measles vaccine can immunize against measles

Measles vaccine given with painless and easy-to-administer microneedle patches can immunize against measles at least as well as vaccine given with conventional hypodermic needles, according to research done by the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC).

28 Nov 2012

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread (tenofovir disoproxil fumarate).

28 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).

27 Nov 2012

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Medgenics’ EPODURE Biopump technology for EPO delivery receives U.S. patent

Medgenics, Inc., the developer of BiopumpTM a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced a patent granted by the U.S. Patent and Trademark Office (USPTO) protecting the use of Medgenics' EPODURE Biopump technology for delivery of erythropoietin (EPO).

22 Nov 2012

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

IRIN examines how the WHO's recent declaration that the MenAfriVac meningitis A vaccine can be transported or stored for up to four days without refrigeration will affect immunization campaigns in Africa's meningitis belt, which runs from Senegal to Ethiopia.

22 Nov 2012

Promising results for pneumococcal vaccine

Research published in The Lancet shows that the PHiD-CV10 vaccine is highly effective at protecting children against invasive pneumococcal disease.

21 Nov 2012

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

19 Nov 2012

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

The adverse side effects of certain hepatitis C medications can now be replicated and observed in Petri dishes and test tubes, thanks to a research team led by Craig Cameron, the Paul Berg Professor of Biochemistry and Molecular Biology at Penn State University.

17 Nov 2012

New pneumococcal vaccine highly effective in infants

A new conjugate vaccine is highly effective (93–100%) at preventing invasive pneumococcal disease (IPD; meningitis, sepsis, bacteremic pneumonia, and other blood-borne infections) in infants younger than 2 years who are the most vulnerable to infection, according to new research published Online First in The Lancet.

16 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies evaluating LG-7501 were featured in a poster presentation today at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

14 Nov 2012

Abbott releases details on phase 3 hepatitis C registrational program

Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

13 Nov 2012

Weight-based ribavirin undertreats African–American HCV patients

African–Americans with hepatitis C virus genotype 1 infections have lower ribavirin plasma exposures than Caucasian Americans when treated with weight-based ribavirin plus peginterferon.

12 Nov 2012

Hepatitis C News and Research

Latest Hepatitis C News and Research

First Edition: November 30, 2012

Myanmar can build more stable future by investing in vaccines, immunization

Nearly 63,000 people visit online catch-up immunization scheduling tool

Diptheria-tetanus-pertussis vaccine: an interview with Dr. Rudi Eggers, World Health Organisation

Microneedle-based measles vaccine can immunize against measles

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Medgenics’ EPODURE Biopump technology for EPO delivery receives U.S. patent

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

Promising results for pneumococcal vaccine

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

HCV medications' side effects can now be replicated and observed in Petri dishes and test tubes

New pneumococcal vaccine highly effective in infants

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Ligand Pharmaceuticals announces data from LG-7501 preclinical studies on HCV

Abbott releases details on phase 3 hepatitis C registrational program

Weight-based ribavirin undertreats African–American HCV patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in